COL 171

Drug Profile

COL 171

Alternative Names: COL-171

Latest Information Update: 13 Jun 2015

Price : $50

At a glance

  • Originator Collegium Pharmaceutical
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Attention-deficit hyperactivity disorder

Most Recent Events

  • 08 Jun 2015 Collegium Pharmaceutical receives patent allowance for DETERx® technology in USA
  • 26 Feb 2015 Collegium Pharmaceutical receives patent allowance for DETERx® technology in USA
  • 20 Mar 2014 Preclinical development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top